Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
Journal Information
Full Title: Eur Respir J
Abbreviation: Eur Respir J
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pulmonary Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest: R.M. Savic and E. Nuermberger report support for the present work from TB Alliance and National Institutes of Health. In addition, E. Nuermberger also reports advisory board participation with Janssen, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose."
"Conflict of interest: R.M. Savic and E. Nuermberger report support for the present work from TB Alliance and National Institutes of Health. In addition, E. Nuermberger also reports advisory board participation with Janssen, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose. Support statement: This work was supported by NIH grant R01AI-111992. Funding information for this article has been deposited with the Crossref Funder Registry."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025